Patents by Inventor Gregory Lazar

Gregory Lazar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS AND IMMUNOFILTERING
    Publication number: 20160068588
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: September 14, 2015
    Publication date: March 10, 2016
    Inventors: Matthew J. Bernett, Bassil Dahiyat, John Desjarlais, Gregory A. Lazar, Gregory L. Moore
  • Fc Variants with Increased Affinity for FcyRIIc
    Publication number: 20150232567
    Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: December 19, 2014
    Publication date: August 20, 2015
    Inventors: GREGORY LAZAR, WEI DANG, JOHN DESJARLAIS, SHER BAHADUR KARKI, OMID VAFA, ROBERT HAYES
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20150152183
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: June 27, 2014
    Publication date: June 4, 2015
    Inventors: Aaron Chamberlain, Bassil Dahiyat, John Desjarlais, Sher Bahadur Karki, Gregory Lazar
  • ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20150110791
    Abstract: The present invention relates to anti-transferrin receptor antibodies and methods of their use.
    Type: Application
    Filed: May 20, 2014
    Publication date: April 23, 2015
    Applicant: GENENTECH, INC.
    Inventors: Yin Zhang, Joy Yu Zuchero, Jasvinder Atwal, Jessica Couch, Mark S. Dennis, James A. Ernst, Ryan J. Watts, Gregory A. Lazar
  • OPTIMIZED Fc VARIANTS
    Publication number: 20150030592
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: August 12, 2014
    Publication date: January 29, 2015
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • OPTIMIZED Fc VARIANTS
    Publication number: 20150031862
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 29, 2015
    Inventors: Gregory LAZAR, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • OPTIMIZED Fc VARIANTS
    Publication number: 20150010543
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 8, 2015
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • OPTIMIZED Fc VARIANTS
    Publication number: 20150010550
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: August 12, 2014
    Publication date: January 8, 2015
    Inventors: Gregory Lazar, Wei Dang, John Desjarlais, Sher Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • Immunoglobulins insertions, deletions, and substitutions
    Patent number: 8883147
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Grant
    Filed: March 18, 2013
    Date of Patent: November 11, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory Lazar, Bassil Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • ANTIBODIES WITH MODIFIED ISOELECTRIC POINTS
    Publication number: 20140249297
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Application
    Filed: January 27, 2014
    Publication date: September 4, 2014
    Applicant: XENCOR, INC.
    Inventors: Gregory A. LAZAR, Bassil I. DAHIYAT, Matthew J. BERNETT
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20140112924
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: December 27, 2013
    Publication date: April 24, 2014
    Applicant: XENCOR, INC.
    Inventors: GREGORY A. LAZAR, MATTHEW J. BERNETT
  • FC VARIANTS THAT EXTEND ANTIBODY HALF-LIFE
    Publication number: 20140056879
    Abstract: The invention relates generally to compositions and methods for altering the serum half-life in vivo of an antibody.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: XENCOR, INC.
    Inventor: GREGORY A. LAZAR
  • Antibodies with modified isoelectric points
    Patent number: 8637641
    Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.
    Type: Grant
    Filed: July 29, 2011
    Date of Patent: January 28, 2014
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory A. Lazar, Matthew J. Bernett
  • CTLA4-Ig immunoadhesins
    Patent number: 8629113
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: January 14, 2014
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Optimized Fc Variants
    Publication number: 20130209445
    Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
    Type: Application
    Filed: March 8, 2013
    Publication date: August 15, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory A. Lazar, Wei Dang, John Desjarais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
  • NOVEL IMMUNOGLOBULINS INSERTIONS, DELETIONS, AND SUBSTITUTIONS
    Publication number: 20130202599
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 8, 2013
    Applicant: Xencor, Inc.
    Inventors: Gregory Lazar, Bassil Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • ANTIBODY VARIANTS WITH ENHANCED COMPLEMENT ACTIVITY
    Publication number: 20130122001
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Application
    Filed: January 22, 2013
    Publication date: May 16, 2013
    Applicant: XENCOR, INC.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • NOVEL CTLA4-IG IMMUNOADHESINS
    Publication number: 20130089550
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Application
    Filed: December 10, 2012
    Publication date: April 11, 2013
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Antibody variants with enhanced complement activity
    Patent number: 8362210
    Abstract: The present invention relates to novel Fc variants that comprise at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc receptor or ligand (e.g., Fc gamma R, C1q). Additionally, the Fc variants have altered complement dependent cytotoxicity (CDC) activity and/or antibody-dependent cell-mediated cytotoxicity (ADCC). The invention further provides methods and protocols for the application of said Fc variants, particularly for therapeutic purposes.
    Type: Grant
    Filed: January 19, 2011
    Date of Patent: January 29, 2013
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Sher Bahadur Karki, Gregory L. Moore
  • CTLA4-Ig immunoadhesins
    Patent number: 8329867
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: December 11, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett